ArticleTrials2026

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Gertjan J L Kaspers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.